Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of nebulized arformoterol tartrate in COPD
CTR20242656Phase 3Active
- Sponsor
- Hechen Pharmaceutical
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of arformoterol in chronic obstructive pulmonary disease (COPD), sponsored by Hechen Pharmaceutical. Started Aug 2024; status: active.
02
Drugs
arformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20242656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242656.